Research programme : skin disorder therapeutics - Evommune
Latest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator Evommune
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for research development in Skin-disorders in USA (Parenteral)
- 28 Dec 2024 No recent reports of development identified for research development in Skin-disorders in USA (PO)
- 28 Dec 2024 No recent reports of development identified for research development in Skin-disorders in USA (Topical)